Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PCRX
stocks logo

PCRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
200.52M
+7.09%
0.902
-0.93%
186.87M
+10.62%
0.765
+23.39%
196.57M
+8.54%
0.815
+10.14%
Estimates Revision
The market is revising Downward the revenue expectations for Pacira BioSciences, Inc. (PCRX) for FY2025, with the revenue forecasts being adjusted by -0.94% over the past three months. During the same period, the stock price has changed by -9.34%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.94%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.14%
In Past 3 Month
Stock Price
Go Down
down Image
-9.34%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Pacira Biosciences Inc (PCRX.O) is 7.06, compared to its 5-year average forward P/E of 13.04. For a more detailed relative valuation and DCF analysis to assess Pacira Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
13.04
Current PE
7.06
Overvalued PE
18.72
Undervalued PE
7.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.30
Undervalued EV/EBITDA
5.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.83
Current PS
0.00
Overvalued PS
4.20
Undervalued PS
1.46
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 695.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PCRX News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Pacira BioSciences Grants 2,200 Restricted Stock Units to New Employees
select
2025-11-26 (ET)
2025-11-26
16:03:12
Pacira Initiates Patent Infringement Legal Action Against WhiteOak Group and Qilu
select
2025-11-06 (ET)
2025-11-06
16:31:48
Pacira lowers FY25 revenue forecast to $725M-$735M, down from $730M-$750M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Globenewswire
Pacira BioSciences Grants 2,200 Restricted Stock Units to New Employees
  • Employee Incentive Program: On December 1, 2025, Pacira granted 2,200 restricted stock units to two new employees under its Amended and Restated 2014 Inducement Plan, serving as a crucial incentive to attract talent and enhance the company's ability to retain key personnel.
  • Equity Grant Details: Each restricted stock unit represents the contingent right to receive one share of Pacira common stock, with vesting occurring in four equal annual installments starting December 1, 2026, ensuring employees remain with the company to realize their equity benefits.
  • Compliance and Approval: The equity awards were approved by the People & Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), without requiring stockholder approval, demonstrating the company's flexibility and compliance in talent management.
  • Strategic Company Direction: This equity incentive not only reflects Pacira's commitment to its new employees but also indicates the company's ongoing investment and development in the non-opioid pain management sector, aiming to enhance its competitive edge through innovative therapies.
[object Object]
Preview
5.0
12-03Newsfilter
Pacira Grants 2,200 Restricted Stock Units to New Employees
  • Employee Incentive Program: On December 1, 2025, Pacira BioSciences granted a total of 2,200 restricted stock units to two new employees under its Amended Inducement Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the non-opioid pain management market.
  • Stock Unit Details: Each restricted stock unit represents the contingent right to receive one share of common stock, vesting in four equal annual installments starting December 1, 2026, ensuring employees remain with the company to earn their awards, which promotes long-term commitment.
  • Board Approval: The stock awards were approved by the People & Compensation Committee of the Board, in compliance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent management, which bolsters investor confidence.
  • Company Background: Pacira focuses on innovative non-opioid pain therapies with several commercial products aimed at improving patient quality of life, and is advancing new therapies, further expanding its market share in the healthcare sector.
[object Object]
Preview
8.5
11-29Globenewswire
PharmaCorp Acquires 3 Pharmacies, Reports 9.4% Revenue Growth in Q3
  • Revenue Growth: PharmaCorp reported a 9.4% year-over-year revenue increase in Q3 2025, driven by continuous growth in prescription volumes and front-store sales, highlighting the company's organic growth potential across its pharmacy network.
  • Acquisition Expansion: Following the quarter-end, PharmaCorp completed the acquisition of three pharmacies located in Western and Eastern Canada, further enhancing its scale and capabilities to support its coast-to-coast strategic ambitions.
  • Operational Efficiency Improvement: The company successfully deployed operational infrastructure to support national scalability, including systems integration and pharmacy onboarding, and while the reported net loss reflects ongoing investments in corporate infrastructure, this will lay the groundwork for future growth.
  • Optimistic Market Outlook: Management expressed encouragement regarding the strong performance of initial acquisitions and emphasized the commitment to maintaining disciplined EBITDA multiples across transactions to achieve long-term accretive growth, indicating confidence in future market opportunities.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pacira Biosciences Inc (PCRX) stock price today?

The current price of PCRX is 23.98 USD — it has decreased -0.87 % in the last trading day.

arrow icon

What is Pacira Biosciences Inc (PCRX)'s business?

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

arrow icon

What is the price predicton of PCRX Stock?

Wall Street analysts forecast PCRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pacira Biosciences Inc (PCRX)'s revenue for the last quarter?

Pacira Biosciences Inc revenue for the last quarter amounts to 179.52M USD, increased 6.49 % YoY.

arrow icon

What is Pacira Biosciences Inc (PCRX)'s earnings per share (EPS) for the last quarter?

Pacira Biosciences Inc. EPS for the last quarter amounts to 0.12 USD, decreased -103.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pacira Biosciences Inc (PCRX)'s fundamentals?

The market is revising Downward the revenue expectations for Pacira BioSciences, Inc. (PCRX) for FY2025, with the revenue forecasts being adjusted by -0.94% over the past three months. During the same period, the stock price has changed by -9.34%.
arrow icon

How many employees does Pacira Biosciences Inc (PCRX). have?

Pacira Biosciences Inc (PCRX) has 790 emplpoyees as of December 05 2025.

arrow icon

What is Pacira Biosciences Inc (PCRX) market cap?

Today PCRX has the market capitalization of 1.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free